IFNB1 and myeloid sarcoma: In multiple sclerosis (MS), disease-modifying therapies (DMTs), such as interferon-beta and glatiramer acetate, are efficient in the initial phases of the disease but have little effect on the atrophy of the gray matter in progressive MS [28].